Selumetinib (AZD6244)
别名: ARRY-142886
中文名称:司美替尼
目录号:S1008 Purity: 99.80%
Selumetinib (AZD6244, ARRY-142886)是一种有效,高选择性的MEK抑制剂,对MEK1的IC50为14 nM,对MEK2的Kd值为530 nM。它也抑制ERK1/2磷酸化,IC50为10 nM,对p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf等没有抑制作用。Selumetinib可抑制细胞增殖、迁移并诱导凋亡。Phase 3。
CAS: 606143-52-6
客户使用Selleck的Selumetinib (AZD6244)发表文献694篇
- Nature, 2024 629(8013):927-936
- Cancer Discov, 2023 13(4):880-909
- Nat Cancer, 2023 4(3):419-435
- Protein Cell, 2023 14(5):350-368
- Cell, 2022 185(11):1974-1985.e12
- Cancer Cell, 2022 S1535-6108(21)00662-0
- Mol Cancer, 2022 21(1):178
- Blood, 2022 blood.2021014304
- Cancer Discov, 2021 candisc.0936.2020
- Cancer Discov, 2021 candisc.0508.2021
- Nat Cell Biol, 2021 23(4):377-390
- Nature, 2020 588(7838):509-514
- Cancer Cell, 2020 37(1):85-103
- Cancer Cell, 2020 13;37(1):104-122e12
- Cancer Cell, 2020 38(6):872-890.e6
- Cancer Cell, 2020 37(3):387-402
- Cancer Cell, 2020 37(2):183-199
- Cancer Discov, 2020 CD-20-0706
- Eur Respir J, 2020 8;2000522
- Nat Med, 2019 25(1):130-140
- Cancer Cell, 2019 36(2):179-193
- Gastroenterology, 2019 157(3):823-837
- Gastroenterology, 2019 156(3):577-581
- Nat Cell Biol, 2019 21(6):778-790
- Nat Med, 2018 24(7):968-977
- Nat Med, 2018 24(7):961-967
- Nat Med, 2018 24(7):954-960
- Cell, 2018 172(4):857-868
- Cancer Cell, 2018 33(1):91-107
- Cancer Cell, 2018 34(3):439-452
- Nat Methods, 2018 15(9):732-740
- Cell Res, 2018 28(7):719-729
- Nat Mater, 2018 17(4):361-368
- Cancer Discov, 2018 8(10):1237-1249
- Cancer Discov, 2018 8(11):1458-1473
- Cell, 2017 168(5):890-903
- Gastroenterology, 2017 152(5):1161-1173
- Cancer Discov, 2017 7(4):369-379
- Gut, 2017 66(6):1106-1115
- Nature, 2016 10.1038/nature19347
- Nat Biotechnol, 2016 34(2):184-191
- Gastroenterology, 2016 150(4):918-30
- Nat Med, 2015 21(9):1038-47
- Cell, 2015 162(6):1271-85
- Cancer Cell, 2015 27(2):240-56
- Cell Res, 2015 10.1038/cr.2015.30
- Nat Genet, 2015 47(9):996-1002
- Cancer Discov, 2015 5(3):264-73
- Cancer Discov, 2015 5(4):358-67
- Nature, 2014 30;514(7524):628-32.
- Mol Cancer, 2014 13:154
- Cancer Discov, 2014 4(1):94-109
- Cancer Discov, 2014 4(1):69-79
- Cancer Discov, 2014 4(10):1214-29
- Blood, 2014 27;124(23):3420-30
- Nature, 2013 504(7478):138-42
- Cancer Discov, 2013 4(2):232-45
- Cancer Discov, 2013 3(4):444-57
- Cancer Discov, 2013 3(3):350-62
- Blood, 2013 121(23):4617-26
- Blood, 2013 121(19):3879-88, S1-8
- Nature, 2012 26;487(7408):505-9.
- Cell, 2012 21;151(5):937-50.
- Cancer Discov, 2012 2(5):414-24
- Cancer Discov, 2012 2(11):1036-47
- Gut, 2012 61(2):202-13
- J Thorac Oncol, 2012 7(2):272-80
- Nat Genet, 2011 44(2):133-9
- Nat Genet, 2011 43(11):1119-26
- Nature, 2010 468(7326):973-7
- Nature, 2010 468(7326):968-72
- Nat Commun, 2024 15(1):8002
- Nat Commun, 2024 15(1):6919
- Nat Commun, 2024 15(1):2503
- Nat Commun, 2024 15(1):2843
- Cell Death Differ, 2024 10.1038/s41418-024-01316-3
- Mol Syst Biol, 2024 10.1038/s44320-024-00081-2
- Cell Rep, 2024 43(10):114831
- Cell Rep, 2024 43(4):114044
- Cell Commun Signal, 2024 22(1):411
- Oncogene, 2024
- Oncogene, 2024 43(6):395-405
- iScience, 2024 27(1):108696
- Mol Ther Oncolytics, 2024 32(2):200783
- Pharmaceutics, 2024 16(3)371
- Cancers (Basel), 2024 16(23)3941
- Neoplasia, 2024 50:100983
- Sci Rep, 2024 14(1):24488
- PLoS Comput Biol, 2024 20(10):e1012488
- Pharmacol Res Perspect, 2024 12(3):e1203
- World J Oncol, 2024 15(3):492-505
- World J Oncol, 2024 15(2):192-208
- Cancer Res Commun, 2024 4(7):1863-1880
- Mol Cell, 2023 83(5):803-818.e8
- Cell Rep Med, 2023 10.1016/j.xcrm.2023.101286
- Cancer Res, 2023 83(2):285-300
- J Biomed Sci, 2023 30(1):72
- Pharmacol Res, 2023 197:106955
- Curr Biol, 2023 33(13):2728-2741.e3
- Cell Death Dis, 2023 14(6):373
- Cell Rep, 2023 42(1):111972
- Cell Commun Signal, 2023 21(1):144
- Front Immunol, 2023 14:1168444
- Mol Oncol, 2023 10.1002/1878-0261.13396
- Oncogenesis, 2023 10.1038/s41389-023-00496-w
- Clin Sci (Lond), 2023 137(1):1-15
- iScience, 2023 26(5):106695
- iScience, 2023 26(3):106082
- iScience, 2023 26(6):106924
- Int J Mol Sci, 2023 24(20)15110
- Int J Mol Sci, 2023 24(17)13418
- Int J Mol Sci, 2023 24(3)2782
- Int J Mol Sci, 2023 24(2)1668
- Mol Cancer Res, 2023 21(4):316-331
- Cell Signal, 2023 106:110634
- Sci Rep, 2023 13(1):12424
- Molecules, 2023 28(2)692
- Development, 2023 150(10)dev201371
- Int J Med Sci, 2023 20(1):125-135
- J Pharmacol Exp Ther, 2023 385(2):106-116
- Int J Clin Oncol, 2023 10.1007/s10147-023-02318-w
- Exp Ther Med, 2023 25(6):243
- Cytotechnology, 2023 75(3):243-253
- Res Sq, 2023 rs.3.rs-2922216
- bioRxiv, 2023 2023.11.22.568378
- Cell Genom, 2023 3(9):100387
- Res Sq, 2023 rs.3.rs-2817876
- bioRxiv, 2023 2023.07.23.550235
- NAR Cancer, 2023 5(3):zcad038
- Cell Rep Methods, 2023 3(10):100599
- Nat Commun, 2022 13(1):1691
- Nat Commun, 2022 13(1):6239
- Nat Commun, 2022 13(1):6323
- Nat Commun, 2022 13(1):6226
- Cell Rep Med, 2022 3(9):100741
- Bone Res, 2022 10(1):27
- Clin Cancer Res, 2022 ccr.22.1052
- J Exp Clin Cancer Res, 2022 41(1):210
- Proc Natl Acad Sci U S A, 2022 119(3)e2114134119
- Mol Syst Biol, 2022 18(8):e10855
- Int J Biol Sci, 2022 18(11):4357-4371
- Cell Death Dis, 2022 13(11):921
- JCI Insight, 2022 7(1)e147819
- JCI Insight, 2022 e156928
- Stem Cell Res Ther, 2022 13(1):197
- J Transl Med, 2022 20(1):541
- Breast Cancer Res, 2022 24(1):41
- Front Immunol, 2022 13:762080
- Glia, 2022 70(10):1850-1863
- iScience, 2022 25(10):105182
- Cancer Sci, 2022 113-10:3428-3436
- Mol Cancer Ther, 2022 MCT-22-0004
- Int J Mol Sci, 2022 23(14)7631
- J Cell Physiol, 2022 10.1002/jcp.30705
- Am J Cancer Res, 2022 12(1):247-264
- Cancers (Basel), 2022 14(6)1575
- Cancers (Basel), 2022 14(23)5833
- Cancers (Basel), 2022 14(7)1773
- Cancers (Basel), 2022 14(3)581
- Cancers (Basel), 2022 14(12)3015
- J Pers Med, 2022 12(7)1080
- Front Oncol, 2022 12:1045521
- Sci Rep, 2022 12(1):14395
- Sci Rep, 2022 12(1):1626
- Stem Cells Int, 2022 2022:8540535
- Toxicol Appl Pharmacol, 2022 437:115886
- Front Genet, 2022 13:942166
- Biochem Biophys Res Commun, 2022 607:36-43
- SLAS Discov, 2022 S2472-5552(22)12517-7
- Leuk Lymphoma, 2022 63(2):404-415
- JTO Clin Res Rep, 2022 3(11):100405
- NAR Cancer, 2022 4(4):zcac032
- ACS Pharmacol Transl Sci, 2022 5(9):724-734
- Discov Oncol, 2022 13(1):26
- Nat Commun, 2021 12(1):2606
- J Extracell Vesicles, 2021 10(8):e12091
- Cell Death Differ, 2021 10.1038/s41418-021-00855-3
- Dev Cell, 2021 S1534-5807(21)00995-3
- J Exp Clin Cancer Res, 2021 40(1):22
- Cancer Res, 2021 81(11):2918-2929
- Cancer Res, 2021 canres.1895.2020
- Cancer Lett, 2021 502:25-33
- Cancer Lett, 2021 510:37-47
- Cancer Lett, 2021 527:10-23
- Cell Rep, 2021 35(11):109238
- Cell Rep, 2021 35(8):109181
- Cell Chem Biol, 2021 S2451-9456(21)00356-1
- Oncogene, 2021 10.1038/s41388-021-02097-6
- Oncogene, 2021 10.1038/s41388-021-01917-z
- JCI Insight, 2021 6(17)148392
- Cell Biosci, 2021 11(1):40
- Front Immunol, 2021 12:657071
- Mol Oncol, 2021 10.1002/1878-0261.13153
- J Clin Endocrinol Metab, 2021 dgab020
- iScience, 2021 24(9):103074
- Mol Cancer Ther, 2021 20(4):641-654
- Cancer Sci, 2021 112(5):1987-1996
- Mol Cancer Ther, 2021 20(9):1653-1662
- Int J Mol Sci, 2021 22(24)13187
- Front Pharmacol, 2021 12:804327
- Int J Mol Sci, 2021 22(19)10204
- Front Cell Dev Biol, 2021 9:661122
- J Virol, 2021 JVI.00180-21
- Oncotarget, 2021 12(7):674-685
- J Cell Mol Med, 2021 10.1111/jcmm.16968
- Cancers (Basel), 2021 13(4)862
- Cancers (Basel), 2021 13(10)2329
- Cancers (Basel), 2021 13(3)555
- Cancers (Basel), 2021 13(4)740
- Cancers (Basel), 2021 13(6)1408
- Cancers (Basel), 2021 13(4)829
- Cell Signal, 2021 S0898-6568(21)00123-6
- Molecules, 2021 26(19)5858
- Molecules, 2021 26(18)5534
- J Proteome Res, 2021 10.1021/acs.jproteome.1c00550
- J Proteome Res, 2021 10.1021/acs.jproteome.1c00444
- PLoS Comput Biol, 2021 17(11):e1009515
- Drug Metab Dispos, 2021 49(1):53-61
- Int J Med Sci, 2021 18(9):2008-2016
- Genes (Basel), 2021 12(9)1402
- Am J Med Genet B Neuropsychiatr Genet, 2021 10.1002/ajmg.b.32882
- Arch Virol, 2021 166(5):1433-1438
- In Vivo, 2021 35(2):721-729
- J Gastrointest Oncol, 2021 12(3):1020-1030
- Nat Commun, 2020 11(1):3157
- Cancer Commun (Lond), 2020 10.1002/cac2.12092
- Nat Chem Biol, 2020 10.1038/s41589-020-0609-7
- Cell Rep Med, 2020 1(8):100131
- Genome Med, 2020 18;12(1):17
- Dev Cell, 2020 52(5):563-573
- Clin Cancer Res, 2020 10.1158
- Cancer Res, 2020 canres.0448.2020
- Proc Natl Acad Sci U S A, 2020 117(33):20004-20014
- Proc Natl Acad Sci U S A, 2020 202008017
- Cell Death Dis, 2020 29;11(5):406
- Br J Cancer, 2020 22
- Cell Rep, 2020 31(2):107514
- Eur J Cancer, 2020 144:17-30
- Oncogene, 2020 14
- Cell Mol Life Sci, 2020 10.1007/s00018-020-03617-5
- Oncogene, 2020 39(20):4132-4154
- Oncogene, 2020 39(15):3218-3225
- Oncogene, 2020 39(3):703-717
- Front Immunol, 2020 14;11:867
- J Pathol, 2020 e5503
- Cell Mol Gastroenterol Hepatol, 2020 S2352-345X(20)30117-X
- PLoS Pathog, 2020 16(2):e1008307
- Mol Oncol, 2020 26
- Mol Oncol, 2020 10.1002/1878-0261.12673
- J Invest Dermatol, 2020 3 pii: S0022-202X(20)31407-X
- Commun Biol, 2020 3(1):593
- Mol Ther Oncolytics, 2020 18:100-108
- Mol Cancer Ther, 2020 13;molcanther11722019
- Int J Mol Sci, 2020 21(20)E7649
- Int J Mol Sci, 2020 18;21(8):2825
- Front Cell Dev Biol, 2020 8:610
- J Ethnopharmacol, 2020 251:112535
- Cancers (Basel), 2020 12(9)E2586
- Cancers (Basel), 2020 27;12(5)pii: E1087
- Mol Cancer Res, 2020 10.1158/1541-7786.MCR-20-0664
- Mol Cancer Res, 2020 18(4):537-548
- Cancers (Basel), 2020 13;12(2) pii: E436
- Aging (Albany NY), 2020 7;12(9):8221-8240
- Cancers (Basel), 2020 12(7):E1744
- Chem Biol Interact, 2020 315:108910
- Transl Oncol, 2020 14(1):100920
- Eur J Pharmacol, 2020 870:172821
- FASEB J, 2020 10.1096/fj.202000657R
- J Biol Chem, 2020 30 pii: jbc
- Front Oncol, 2020 10:1482
- Viruses, 2020 12(10)E1128
- Sci Rep, 2020 10(1):13124
- Sci Rep, 2020 10(1):21985
- Development, 2020 147(23)dev192351
- Pediatr Blood Cancer, 2020 e28639
- Pathol Oncol Res, 2020 10.1007/s12253-020-00834-y
- Arch Virol, 2020 10.1007/s00705-020-04524-7
- Sci Adv, 2020 22;6(21):eaaz8521
- J Chemother, 2020 32(8):437-444
- bioRxiv, 2020 2020/9/20.4.7.30734
- Mol Biomed, 2020 1(1):12
- Nat Commun, 2019 10(1-:2987
- Nat Commun, 2019 10(1):2197
- Nat Commun, 2019 10(1):5549
- Nat Commun, 2019 10(1):2919
- Nat Commun, 2019 10(1):5143
- J Clin Invest, 2019 10.1172/JCI128678
- Dev Cell, 2019 51(5):602-616.e12
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-19-1398
- Clin Cancer Res, 2019 10.1158/1078-0432.CCR-18-4145
- Redox Biol, 2019 24:101189
- J Exp Clin Cancer Res, 2019 38(1):83
- J Exp Clin Cancer Res, 2019 18;38(1):85
- Cancer Res, 2019 79(10):2494-2510
- EBioMedicine, 2019 49:106-117
- Haematologica, 2019 10.3324/haematol.2018.211110
- Cancer Lett, 2019 442:53-67
- Cell Death Dis, 2019 10(12):871
- Cell Rep, 2019 29(3):573-588
- Br J Cancer, 2019 120(9):941-951
- Cell Rep, 2019 27(3):806-819
- Br J Cancer, 2019 10.1038/s41416-019-0673-5
- Cell Rep, 2019 29(1):118-134
- Br J Cancer, 2019 121(9):758-767
- Acta Pharmacol Sin, 2019 10.1038/s41401-019-0268-y
- Oncogene, 2019 38(18):3402-3414
- Oncogene, 2019 101038/s41388-019-1136-4
- JCI Insight, 2019 4(4)
- Front Immunol, 2019 10:2020
- Transl Psychiatry, 2019 9(1):306
- PLoS Pathog, 2019
- Mol Oncol, 2019 13(2):290-306
- Mol Oncol, 2019 13(7):1467-1489
- Thyroid, 2019 29(1):79-92
- Oncogenesis, 2019 8(9):50
- Cells, 2019 8(12)
- Cells, 2019 8(8)
- Stem Cell Reports, 2019
- Biochem Pharmacol, 2019 169:113640
- Cancer Sci, 2019 110(8):2529-2539
- Mol Cancer Ther, 2019 18(8):1439-1450
- Front Pharmacol, 2019 10:1159
- Target Oncol, 2019 14(5):619-626
- Oncotarget, 2019 10(14):1440-1457
- Oncotarget, 2019 10(56):5755-5767
- Int J Oncol, 2019 54(3):1123-1133
- Cancers (Basel), 2019 11(11)
- Transl Oncol, 2019 13(2):201-211
- Transl Oncol, 2019 12(8):1015-1025
- Lab Invest, 2019 10.1038/s41374-019-0274-1
- Am J Physiol Lung Cell Mol Physiol, 2019 316(1):L20-L34
- Sci Rep, 2019 9(1):1897
- Sci Rep, 2019 9(1):13308
- Sci Rep, 2019 9(1):7779
- Molecules, 2019 24(3)
- Mol Carcinog, 2019 10.1002/mc.23123
- PLoS Genet, 2019 15(4):e1008077
- Invest Ophthalmol Vis Sci, 2019 60(1):349-357
- Invest Ophthalmol Vis Sci, 2019 60(7):2764-2772
- Pigment Cell Melanoma Res, 2019 10.1111/pcmr.12812
- Pigment Cell Melanoma Res, 2019 32(2):280-291
- Cell Cycle, 2019 18(13):1513-1522
- Cell Cycle, 2019 18(5):596-604
- Heliyon, 2019 6(1):e03031
- Mol Pharmacol, 2019 96(1):36-46
- J Mol Endocrinol, 2019 63(3):199-213
- Invest New Drugs, 2019 10.1007/s10637-019-00795-3
- Oncol Lett, 2019 17(3):3569-3575
- Pathol Oncol Res, 2019 25(2):769-775
- Anticancer Res, 2019 39(7):3785-3793
- Sci Adv, 2019 5(8):eaav8463
- Transl Cancer Res, 2019 8(4):1224-1232
- Sci Transl Med, 2018 10(450)
- Nat Commun, 2018 9(1):579
- Nat Commun, 2018 9(1):5416
- Nat Commun, 2018 9(1):2434
- Nat Commun, 2018 9(1):28
- Mol Cell, 2018 70(5):949-960
- J Exp Med, 2018 215(6):1693-1708
- Biomaterials, 2018 156:258-273
- Theranostics, 2018 8(5):1256-1269
- Theranostics, 2018 8(8):2134-2146
- Genome Med, 2018 10(1):90
- Clin Cancer Res, 2018 24(19):4854-4864
- Clin Cancer Res, 2018 24(24):6367-6382
- Cancer Res, 2018 78(6):1444-1456
- EMBO Mol Med, 2018 10(9)
- Mol Psychiatry, 2018 23(2):444-458
- PLoS Biol, 2018
- Cancer Lett, 2018 414:268-277
- Cell Death Dis, 2018 9(11):1052
- Cell Death Dis, 2018 9(2):31
- Cell Death Dis, 2018 9(2):123
- Br J Cancer, 2018 119(6):713-723
- Oncogene, 2018 37(39):5340-5354
- Breast Cancer Res, 2018 20(1):9
- J Transl Med, 2018 16(1):114
- Br J Haematol, 2018 182(6):921-924
- Int J Cancer, 2018 142(2):381-391
- Oncogenesis, 2018 7(9):67
- Bioinformatics, 2018 34(17):i997-i1004
- Bioinformatics, 2018 34(23):4079-4086
- Mol Cancer Ther, 2018 17(11-:2329-2340
- Cancer Sci, 2018 109(12):3816-3825
- Front Pharmacol, 2018 8:988
- Int J Mol Sci, 2018 19(7)
- Am J Physiol, Cell Physiol, 2018
- Oncotarget, 2018 9(100):37352-37366
- Oncotarget, 2018 9(74):33995-34008
- Mol Cancer Res, 2018 16(11):1773-1784
- Cancers (Basel), 2018 10(11)
- J Biol Chem, 2018 293(23):9113-9123
- Cell Signal, 2018 44:127-137
- Cell Signal, 2018 42:11-20
- Sci Rep, 2018 8(1):850
- Sci Rep, 2018
- Cell Physiol Biochem, 2018 49(4):1499-1511
- Pigment Cell Melanoma Res, 2018 31(2):253-266
- Cell Cycle, 2018 17(4):428-438
- Mol Cell Endocrinol, 2018 474:20-34
- J Clin Med, 2018 7(5)
- BMC Cancer, 2018 18(1):542
- BMC Cancer, 2018 18(1):595
- PLoS One, 2018 13(2):e0191890
- Med Sci Monit, 2018 24:8048-8055
- Med Sci Monit, 2018 24:3002-3010
- Oncol Lett, 2018 16(1):326-334
- Exp Lung Res, 2018 44(7):332-343
- Nat Commun, 2017 8;8:15617
- Nat Commun, 2017 8(1):1090
- J Clin Invest, 2017 127(6):2081-2090
- Neuro Oncol, 2017 20(6):764-775
- J Exp Med, 2017 214(6):1691-1710
- Nat Chem Biol, 2017 13(1):119-126
- Theranostics, 2017 7(5):1114-1132
- Clin Cancer Res, 2017 23(21):6567-6579
- Cancer Lett, 2017 408:130-137
- Br J Cancer, 2017 116(8):1065-1076
- Oncogene, 2017 36(45):6348-6358
- JCI Insight, 2017 2(3):e89473
- J Cell Biol, 2017 216(6):1567-1577
- Elife, 2017 6
- Breast Cancer Res, 2017 19(1):105
- J Mater Chem B, 2017 5(20):3658-3666
- Mol Oncol, 2017 11(5):470-490
- Int J Cancer, 2017 140(12):2758-2770
- Mol Cancer Ther, 2017 16(10):2234-2245
- Oncotarget, 2017 9(5):5529-5544
- Oncotarget, 2017
- Oncotarget, 2017 8(8):13174-13185
- Oncotarget, 2017 8(61):104193-104205
- Oncotarget, 2017
- Oncotarget, 2017 8(52):90037-90049
- Oncotarget, 2017 8(7):11460-11479
- Oncotarget, 2017 8(49):84697-84713
- Oncotarget, 2017 9(3):3815-3829
- Oncotarget, 2017 8(22):36628-36638
- Oncotarget, 2017 8(55):94606-94618
- Oncotarget, 2017 8(18):30151-30161
- Oncotarget, 2017 8(19):31666-31681
- J Biol Chem, 2017 292(10):3970-3976
- Sci Rep, 2017 7:44123
- ACS Omega, 2017 2(11):7868-7880
- J Steroid Biochem Mol Biol, 2017 165(Pt B):258-267
- Int J Biochem Cell Biol, 2017 85:149-158
- Front Physiol, 2017 7:682
- PLoS One, 2017 12(9):e0184861
- PLoS One, 2017 12(1):e0170445
- Am J Reprod Immunol, 2017 78(4)
- Medchemcomm, 2017 8(1):88-95
- SLAS Discov, 2017 22(5):507-515
- Biochemistry, 2017 56(34):4449-4456
- Biotechnol Lett, 2017 39(7):1069-1077
- Urol Oncol, 2017 35(1):32
- Melanoma Res, 2017 27(6):545-557
- Anticancer Res, 2017 37(2):607-614
- Nat Commun, 2016 7:13615
- Nat Commun, 2016 7:11363
- J Clin Invest, 2016 126(1):349-64
- Hepatology, 2016 64(2):488-500
- Genome Biol, 2016 17:80
- Clin Cancer Res, 2016 10.1158/1078-0432.CCR-15-2987
- Clin Cancer Res, 2016 22(21):5312-5321
- Clin Cancer Res, 2016 22(21):5370-5382
- Clin Cancer Res, 2016 22(24):6021-6030
- Leukemia, 2016 30(9):1832-43
- Cancer Res, 2016 76(3):675-85
- Cancer Res, 2016 76(3):724-35
- Cancer Res, 2016 76(20):6095-6106
- Cell Death Dis, 2016 7(10):e2432
- Cell Death Dis, 2016 7(11):e2456
- Cell Chem Biol, 2016 23(12):1550-1559
- Oncogene, 2016 35(38):5010-20
- Elife, 2016 10.7554/eLife.11414
- Elife, 2016 5
- Elife, 2016 10.7554/eLife.18489
- Elife, 2016 5e12116
- Mol Cell Proteomics, 2016 15(3):1139-50
- Mol Oncol, 2016 10(1):101-12
- J Invest Dermatol, 2016 136(12):2475-2484
- Mol Cancer Ther, 2016 15(1):172-83
- Mol Cancer Ther, 2016 15(7):1460-71
- Oncotarget, 2016
- Oncotarget, 2016 7(7):7960-9
- Oncotarget, 2016 7(31):49597-49610
- Oncotarget, 2016 7(15):19575-88
- Oncotarget, 2016 7(8):9102-17
- Oncotarget, 2016 7(21):30907-23
- Oncotarget, 2016
- Oncotarget, 2016 7(40):65147-65156
- Oncotarget, 2016 7(12):13797-809
- Oncotarget, 2016 7(4):3947-65
- Oncotarget, 2016 7(48):78396-78411
- Oncotarget, 2016 7(50):83424-83436
- Oncotarget, 2016 7(50):82185-82199
- Oncotarget, 2016
- Oncotarget, 2016 7(12):13886-901
- Oncotarget, 2016 7(2):1598-607
- J Neurosci, 2016 36(44):11196-11207
- Mol Cancer Res, 2016
- Int J Oncol, 2016 49(3):953-60
- Mol Cancer Res, 2016 14(12):1204-1216
- Cancers (Basel), 2016
- Mol Pharm, 2016 13(11):3724-3735
- J Biol Chem, 2016 291(41):21694-21702
- Sci Rep, 2016 6:34933
- Sci Rep, 2016
- Sci Rep, 2016 6:26803
- BMC Genomics, 2016 17(1):723
- PLoS One, 2016 11(5):e0155893
- PLoS One, 2016 11(1):e0147682
- PLoS One, 2016 11(9):e0162634
- Biochemistry, 2016 10.1172/JCI81468
- Thorac Cancer, 2016 7(3):279-87
- PeerJ, 2016 4:e1683
- Leuk Res, 2016 50:1-10
- Integr Biol, 2016 8(1):73-90
- Methods Enzymol, 2016 568:557-80
- Nat Commun, 2015 6:8583
- Nat Commun, 2015 6:7769
- Neuro Oncol, 2015 10.1093/neuonc/nou369
- Clin Cancer Res, 2015 10.1158/1078-0432.CCR-15-0013
- Leukemia, 2015 29(3):705-14
- Leukemia, 2015 29(4):828-38
- Cancer Res, 2015 10.1158/0008-5472.CAN-15-0370
- Cancer Res, 2015 75(5):880-91
- Proc Natl Acad Sci U S A, 2015 112(32):9990-5
- EMBO Mol Med, 2015 7(9):1104-18
- Nano Lett, 2015 15(12):8032-43
- J Natl Cancer Inst, 2015 108(6):djv406
- Cancer Lett, 2015 364(1):70-8
- Oncogene, 2015 10.1038/onc.2015.97
- Oncogene, 2015 10.1038/onc.2015.12
- Elife, 2015
- J Transl Med, 2015 13:210
- Mol Cell Proteomics, 2015 10.1074/mcp.M115.049783 mcp.M115.049783.
- Mol Oncol, 2015 9(7):1434-46
- J Invest Dermatol, 2015 135(7):1863-1872
- Mol Cancer Ther, 2015 14(12):2831-9
- Mol Cancer Ther, 2015 14(12):2700-11
- Mol Cancer Ther, 2015 14(5):1236-46
- Eur Neuropsychopharm, 2015 10.1016/j.euroneuro.2014.12.007
- Respir Res, 2015
- Oncotarget, 2015 6(19):17491-500
- Oncotarget, 2015
- Oncotarget, 2015 6(16):14472-87
- Oncotarget, 2015 6(32):33397-409
- Oncotarget, 2015 6(5):3165-77
- Oncotarget, 2015
- Oncotarget, 2015 6(32):33623-35
- Oncotarget, 2015 6(31):31792-804
- Oncotarget, 2015 6(11):8698-708
- Oncotarget, 2015
- J Neurosci, 2015 35(3):972-84
- J Neurosci, 2015 35(7):3034-47
- Int J Oncol, 2015 47(3):849-56
- Am J Physiol Endocrinol Metab, 2015 308(10):E899-911
- Antimicrob Agents Chemother, 2015 59(2):1088-99
- FASEB J, 2015 10.1096/fj.14-267278
- Cell Signal, 2015 27(10):1939-48
- J Biol Chem, 2015 290(28):17495-504
- Cell Signal, 2015 27(11):2191-200
- Gynecol Oncol, 2015 138(1):165-73
- Gynecol Oncol, 2015 139(1):118-26
- Front Oncol, 2015 5:135
- Pigment Cell Melanoma Res, 2015 28(5):572-89
- J Biotechnol, 2015 10.1016/j.jbiotec.2015.01.012
- Biochem J, 2015 465(2):227-38
- J Cancer, 2015 6(12):1195-205
- BMC Cancer, 2015 15:894
- PLoS One, 2015 10(9):e0137917
- PLoS One, 2015 10(12):e0143847
- Exp Cell Res, 2015 332(1):1-10
- Radiat Oncol, 2015 10:214
- Biochem Biophys Res Commun, 2015 456(3):821-6
- Prostate, 2015 10.1002/pros.22945
- Nat Commun, 2014 5:3901
- Nucleic Acids Res, 2014 42(8):5083-96
- Clin Cancer Res, 2014 20(23):6023-33
- Leukemia, 2014 10.1038/leu.2014.187.
- Cancer Res, 2014 74(10):2825-34
- Cancer Res, 2014 74(20):5866-77
- Cell Death Dis, 2014 5:e1434
- Oncogene, 2014 33(33):4236-41
- Oncogene, 2014 10.1038/onc.2014.392
- Gastric Cancer, 2014 10.1007/s10120-014-0444-1
- Sci Signal, 2014 7(357):ra122
- Sci Signal, 2014 7(311):ra12
- J Invest Dermatol, 2014 134(2):366-73
- Mol Cancer Ther, 2014 13(2):353-63
- Mol Cancer Ther, 2014 13(7):1894-906
- Mol Cancer Ther, 2014 10.1158/1535-7163.MCT-14-0452
- Oncotarget, 2014
- Oncotarget, 2014 5(21):10732-44
- Mol Cell Biol, 2014 34(22):4088-103
- Mol Nutr Food Res, 2014 58(3):528-36
- Mol Cancer Res, 2014 12(10):1509-19
- FASEB J, 2014 10.1096/fj.13-247924
- Pigment Cell Melanoma Res, 2014 27(3):479-84
- Cell Cycle, 2014
- Pigment Cell Melanoma Res, 2014 27(6):1154-8
- Sensors (Basel), 2014 14(3):5074-117
- Endocr Relat Cancer, 2014 21(2):161-73
- BMC Cancer, 2014 14(1):240
- PLoS One, 2014 9(2):e83957
- PLoS One, 2014 9(12):e115068
- Exp Cell Res, 2014 327(2):340-52
- Virology, 2014 468-470C:490-503
- PLoS One, 2014 9(10):e110306
- PLoS One, 2014 9(5):e97938
- PLoS One, 2014 9(2):e89646
- Cancer Biol Ther, 2014 15(9):1239-47
- Hum Mol Genet, 2014 23(1):1-11
- Tumor Biol, 2014 35(10):9759-67
- Radiat Res, 2014
- Neuroscience, 2014 562:69-74
- Biochem Biophys Res Commun, 2014 452(4):958-61
- Cancer Chemother Pharmacol, 2014 73(2):259-70
- Assay Drug Dev Technol, 2014 12(9-10):514-26
- J Clin Invest, 2013 123(6):2551-63
- J Clin Invest, 2013 123(5):2155-68
- J Clin Invest, 2013 124(1):156-68
- Hepatology, 2013 59(4):1435-47
- Exp Mol Med, 2013 45:e64
- Clin Cancer Res, 2013 19(20):5749-57
- Clin Cancer Res, 2013 19(9):2584-91
- Clin Cancer Res, 2013 19(1):118-27
- Clinical Cancer Research, 2013 19(9)
- Cancer Res, 2013 73(23):7101-10
- Cancer Res, 2013 73(20):6346-58
- Cancer Res, 2013 73(15):4840-51
- Proc Natl Acad Sci USA, 2013 10.1038/onc.2013.389
- J Natl Cancer Inst, 2013 105(1):33-46
- Mol Syst Biol, 2013
- Cell Rep, 2013 4(6):1090-9
- Oncogene, 2013 33(33):4236-41
- Sci Signal, 2013 6(271):ra25
- Sci Signal, 2013 5(206):ra3
- Sci Signal, 2013
- Mol Cancer Ther, 2013 12(6):1131-9
- Cancer Sci, 2013 104(7):896-903
- Oncotarget, 2013 4(9):1496-506
- J Neurosci, 2013 33(10):4280-94
- Mol Cell Biol, 2013 33(20):4051-67
- J Mol Cell Cardiol, 2013 59:139-47
- Skelet Muscle, 2013 3(1):17
- Carcinogenesis, 2013 34(3):638-46
- Pigment Cell Melanoma Res, 2013 26(4):518-26
- Cell Cycle, 2013 12(13):2073-83
- Pigment Cell Melanoma Res, 2013
- Oncol Rep, 2013 29(2):812-8
- PLoS One, 2013 500(7461):222-6
- PLoS One, 2013 8(10):e77243
- Exp Cell Res, 2013 319(12):1732-43
- PLoS One, 2013 8(7):e68817
- J Surg Res, 2013 184(2):898-906
- University of Southampton, 2013 University of Southampton
- J Clin Invest, 2012 122(7):2637-51
- Nat Chem Biol, 2012 8(11):905-912
- Cell Death Differ, 2012 19(12):2029-39
- Proc Natl Acad Sci U S A, 2012 109(31):E2127-33
- Cardiovasc Res, 2012 93(2):311-9
- Cancer Lett, 2012 316(1):77-84
- Oncogene, 2012 31(27):3277-86
- Sci Signal, 2012 5(224):rs4
- Am J Pathol, 2012 180(6):2462-78
- Mol Cancer Ther, 2012 11(2):317-28
- Am J Physiol Cell Physiol, 2012 304(5):C431-9
- Aging, 2012 4(11):803-822
- J Biol Chem, 2012 287(50):41797-807
- Carcinogenesis, 2012 33(5):956-61
- Endocr Relat Cancer, 2012 19(1):29-38
- Surgery, 2012 152(6):1142-9
- PLoS One, 2012 7(9):e42441
- PLoS One, 2012 7(8):e44146
- PLoS One, 2012 7(1):e29622
- Cancer Biol Ther, 2012 13(1):43-9
- Neuroscience, 2012 206:224-36
- J Biomol Screen, 2012 17(6):813-21
- Biomaterials, 2011 32(35):9197-206
- Cancer Res, 2011 71(15):5067-74
- Mol Syst Biol, 2011 7:489
- J Invest Dermatol, 2011 132(2):356-64
- J Clin Endocrinol Metab, 2011 97(2):E173-82
- Mol Cancer Res, 2011 9(5):545-52
- Endocrinology, 2011 152(7):2589-98
- Mol Endocrinol, 2011 25(12):2041-53
- PLoS One, 2011 6(12):e28973
- Biol Reprod, 2011 85(1):42-50
- Cancer Biol Ther, 2011 12(3):215-28
- Cancer Res, 2010 70(11):4709-18
- Brit J Haematol, 2010 149(4):537-49
- Methods Mol Biol, 2010 661:107-22
- P Natl Acad Sci USA, 2009 106(48):20411-6
化学信息&溶解度
分子量 | 457.68 |
分子式 | C17H15BrClFN4O3 |
CAS号 | 606143-52-6 |
Smiles | CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO |
储存条件(自收到货起) | |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 91 mg/mL ( 198.82 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 92 mg/mL ( 201.01 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 92 mg/mL ( 201.01 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble DMSO : 92 mg/mL ( 201.01 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Water : Insoluble Ethanol : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
4%DMSO
30%PEG300
5%Tween80
61%ddH2O
浓度:5mg/ml
(10.92mM)
操作示例:以 1 mL 工作液为例,取40μL125mg/ml的澄清DMSO储备液加到300μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入610μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。